Edward J. Markey
Amendment 1

| AM | IENDMENT NO Calendar No |
|------|--|
| Pui | rpose: To require a study on access to medication for opioid overdose reversal. |
| IN ' | THE SENATE OF THE UNITED STATES—118th Cong., 1st Sess. |
| | S. 1339 |
| Го | provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. |
| R | eferred to the Committee on and ordered to be printed |
| | Ordered to lie on the table and to be printed |
| A | MENDMENT intended to be proposed by Mr. MARKEY (for himself, Mr. Braun, and Mr. Marshall) |
| Viz | : |
| 1 | At the appropriate place, insert the following: |
| 2 | SEC STUDY ON NALOXONE ACCESS. |
| 3 | (a) In General.—The Comptroller General of the |
| 4 | United States shall conduct a study on actions that may |
| 5 | be taken to ensure appropriate access and affordability of |
| 6 | naloxone for individuals seeking to purchase naloxone. |
| 7 | Such study shall address what is known about— |
| 8 | (1) coverage of naloxone (in any available |
| 9 | form), including whether naloxone can be covered as |
| 10 | an over-the-counter drug under a group health plan |
| 11 | or group or individual health insurance coverage (as |

| Ţ | such terms are defined in section 2791 of the Public |
|----|--|
| 2 | Health Service Act (42 U.S.C. 300gg-91)); |
| 3 | (2) the out-of-pocket cost to consumers pur- |
| 4 | chasing naloxone— |
| 5 | (Λ) with a prescription, with and without |
| 6 | coverage under any such plan or coverage; and |
| 7 | (B) over-the-counter, with and without cov- |
| 8 | erage under any such plan or coverage; and |
| 9 | (3) other factors impacting coverage, including |
| 10 | barriers in covering naloxone as an over-the-counter |
| 11 | drug, the relative net costs of naloxone when pur- |
| 12 | chased over-the-counter without insurance coverage |
| 13 | compared to when purchased with a prescription and |
| 14 | covered under a group health plan or health insur- |
| 15 | ance coverage, and the availability of naloxone pur- |
| 16 | chased and distributed through public health enti- |
| 17 | ties. |
| 18 | (b) REPORT.—Not later than 2 years after the date |
| 19 | of the enactment of this Act, the Comptroller General of |
| 20 | the United States shall submit to Congress a report that |
| 21 | contains the findings of the study conducted under sub- |
| 22 | section (a). |